Drug Trial Radar · NCT06031233
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,082
Planned (sponsor's estimate)
Start
Sep 1, 2023
Primary completion
Jul 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- IsalaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an interventional, explorative, prospective study to show whether shortening of infusion times for patients using nivolumab, pembrolizumab, ipilimumab, trastuzumab, bevacizumab, durvalumab or atezolizumab continues to be associated with an acceptable safety profile. Infusion times will be gradually shortened if tolerability allowes.
Conditions
- Oncology
- Infusion Reaction
Interventions
NivolumabDrug
Gradual shortening of infusion times
PembrolizumabDrug
Gradual shortening of infusion times
IpilimumabDrug
Gradual shortening of infusion times
DurvalumabDrug
Gradual shortening of infusion times
AtezolizumabDrug
Gradual shortening of infusion times
BevacizumabDrug
Gradual shortening of infusion times
TrastuzumabDrug
Gradual shortening of infusion times
RituximabDrug
Gradual shortening of infusion times
InfliximabDrug
Gradual shortening of infusion times
VedolizumabDrug
Gradual shortening of infusion times
TociliuzumabDrug
Gradual shortening of infusion times
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of infusion related reactionsTime frame: During or within 30 minutes after the end of the infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Isala Hospital
Zwolle, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.